Job Trends
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
“Our ultimate goal is to provide a solution to an organ shortage that causes an average of 20 people per day in the U.S. alone to die waiting for an organ transplant,” quoted Rich Boling, the vice-president of corporate advancement at Techshot.
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
Blocking IL-6 pathway may extend duration of immunotherapy and reduce side effects
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
Research Team Combines Multi-Spectral Imaging and Supercomputing
Florida-based Hesperos is changing the paradigm of clinical development with its organ-on-a-chip technology and new research that demonstrates the platform can predict in vivo response to medications and reduce the need for animal testing.
Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial